2018 | |
---|---|
Criterium: | Position: |
Overall Score: | > 1000 |
Total Project Funding per Partner: | > 1000 |
Total Number of Projects: | > 1000 |
Networking Rank (Reputation): | > 1000 |
2016 | |
Criterium: | Position: |
Overall Score: | > 1000 |
Networking Rank (Reputation): | > 1000 |
2015 | |
Criterium: | Position: |
Overall Score: | > 1000 |
Networking Rank (Reputation): | > 1000 |
2012 | |
Criterium: | Position: |
Overall Score: | 900-1000 |
Networking Rank (Reputation): | > 1000 |
Networking Rank (Reputation): | > 1000 |
Total number of projects: 5
As coordinator: 0
As participant: 5
Sole participant: 0
Coordinator / Participant Ratio: 0*
Total project funding [€]: | Projects [No]: | |||||
---|---|---|---|---|---|---|
Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
2021 | 0 | 6.900.000 | 221.813 | 1 | ||
2018 | 0 | 6.701.365 | 302.075 | 1 | ||
2016 | 0 | 3.338.482 | 84.163 | 1 | ||
2015 | 0 | 5.997.139 | 231.085 | 1 | ||
2012 | 0 | 5.946.262 | 991.044 | 1 |
Total number of partners: 35
Partner loyalty:
Frequent Partner: (> 2 projects): 0
Rare Partner: 35
Frequent / Rare Partner Ratio: 0
Start date | Project | acronym | role | funding | partners |
---|---|---|---|---|---|
2021-02-01 | Proof of Principle of the best-in-class therapeutic mRNA cancer vaccine | TIGER | participant | 6.900.000 | 8 |
2018-01-01 | Personalised Treatment For Cystic Fibrosis Patients With Ultra-rare CFTR Mutations (and beyond) | HIT-CF | participant | 6.701.365 | 10 |
2016-06-01 | SUpport and PartnERship for the development of multiple sustainable and market ready value chains in the BIObased economy | SUPERBIO | participant | 3.338.482 | 10 |
2015-05-01 | Clinical Proof of concept for a RNA-targeting Oligonucleotide for a Cystic fibrosis-F508del MEDication | PRO-CF-MED | participant | 5.997.139 | 6 |
2012-07-01 | First Targeted Therapy to FIGHT Hemophagocytic Lymphohistiocytosis (HLH): A novel approach to HLH | FIGHT-HLH | participant | 5.946.262 | 6 |